Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consolidative Immunotherapy +/- SBRT in Metastatic NSCLC
NCT03867175Phase 3Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jun 2019
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Wake Forest University Health Sciences. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03867175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03867175.